SKSean Khozin

Sean Khozin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sean Khozin has a total of 220 co-authors. Here are the top co-authors by number of shared publications:

  • Richard Pazdur

    U.S. Food and Drug Administration, Silver Spring, Maryland, USA

    15 shared publications
  • Patricia Keegan

    Center for Drug Evaluation and Research, US Food and Drug Administration, White Oak, Maryland

    9 shared publications
  • Giuseppe Giaccone

    Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC

    7 shared publications
  • Anish Thomas

    Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA

    6 shared publications
  • Lijun Zhang

    Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland

    6 shared publications
  • Arun Rajan

    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

    5 shared publications

Latest Publications

  • Open Access

    Real World Imaging Data: Opportunities and Challenges (Preprint)

    by Jie Wu, Aline L de Araujo, Sean Khozin, Merel Huisman, Domenico Mastrodicasa, Martin J Willemink

    The amount of data generated in clinical practice is increasing substantially. This has benefited the use of real-world data for real-world evidence in biomedical research. While early real-world evidence efforts focused on structured electronic health record and insurance claims data, advances in analytical methods, such as AI, are expected to further enhance the ability to obtain deeper insights from real-world data. Most recently, real-world imaging data (RWiD) has emerged as a novel and valuable resource. RWiD is enabled by improvements in imaging infrastructure, data standardization, and deidentification technologies. Medical imaging is essential at multiple stages of clinical care, ranging from screening to posttreatment assessment and surveillance. Medical imaging has become a key component of patient management, as it augments clinical decision-making across many medical specialties. RWiD is the retrospective collection of routinely gathered clinical imaging data. Using only radiology reports results in limited information compared to datasets that contain the actual images. Radiology reports primarily focus on clinical decision-making rather than research purposes. Therefore, the actual images add value to real-world datasets. However, using RWiD is challenging due to complex deidentification and harmonization, as well as requirements for file storage, file transfer, and computation. This editorial paper provides an educational overview, including the background, challenges, and opportunities of RWiD, and offers examples of RWiD applications that benefit life sciences and biopharmaceutical use cases.

  • The Use of Artificial Intelligence for Cancer Therapeutic Decision-Making

    by Olivier Elemento, Sean Khozin, Cora N. Sternberg

    Artificial intelligence (AI) has the potential to transform cancer therapeutic decision-making by improving diagnostics and personalizing treatments. This review explores the current and future impact of AI in oncology, focusing on its applications in radiology, pathology, and the potential of Large Language Models (LLMs) in treatment selection. Despite significant advancements, AI integration into clinical workflows is limited due to challenges like data quality, model accuracy, and lack of validation through clinical trials. We propose key strategies to address these challenges, including developing robust multi-center datasets, promoting practical AI model development, researching workflow integration and human-AI collaboration, leveraging lessons from AI in medical imaging, establishing evaluation guidelines, and incentivizing prospective clinical trials. By implementing these strategies, AI can significantly enhance cancer care and patient outcomes, paving the way for its effective integration into oncology practice.


  • Open Access

    Artificial Intelligence in Biomedical Data Analysis: A Comparative Assessment of Large Language Models for Automated Clinical Trial Interpretation and Statistical Evaluation

    by Ravikumar Komandur, Jon McDunn, Nikita Nair, Babacar Fall, Adam P. Dicker, Sean Khozin

    Background Clinical trials provide evidence of the efficacy and safety of experimental treatment regimens. Analysis of data from these trials is a time-intensive process traditionally requiring advanced multidisciplinary expertise in biomedicine, clinical research, biostatistics and data science. Large language models (LLMs), such as OpenAI’s GPT-4 and Google’s Gemini Advanced, present new opportunities for data analysis in medical research by leveraging natural language understanding and data interpretation capabilities. Objective This study investigates the ability of LLMs to analyze and report clinical trial results, starting with de-identified individual patient data. Here, we evaluate two LLMs for their ability to recapitulate the analysis of a clinical trial that evaluated LY2510924 in combination with carboplatin and etoposide for the treatment of extensive-stage small cell lung cancer (ES-SCLC). The main objectives are to (i) assess whether LLMs can be effectively used without specialized machine learning training and (ii) compare LLM-driven analyses to those conducted by experienced data scientists. Methods Data from the Project Data Sphere (PDS) platform were used, and multiple investigators employed both ChatGPT and Gemini Advanced for analysis. A chain-of-thought (CoT) prompting framework was applied to guide the LLMs through a systematic evaluation of baseline characteristics, progression-free survival (PFS), overall survival (OS), safety data, and biomarker information. Results were compared across investigators and LLMs to assess consistency. Results While LLMs could process the trial data and generate relevant insights, discrepancies were observed across the investigators’ analyses, particularly in primary and secondary endpoints. One investigator found a significant improvement in PFS with LY2510924, contradicting other results. Variations in reporting objective response rate (ORR) and adverse event analyses also highlighted challenges in reporting between different LLMs. These discrepancies may be due to differences in LLM capabilities and behaviors, prompting strategies, and potential model drift over time. Conclusion LLMs such as ChatGPT-4 and Gemini Advanced offer promising capabilities in clinical data analysis, though variability in results underscores the need for tailored CoT frameworks and specialized prompting strategies. Addressing issues such as model drift and ensuring consistent model versions are crucial for reliable application. LLMs also show potential to accelerate clinical research by drafting clinical trial reports, but further refinements are needed to ensure accuracy and consistency in their application. The observed discrepancies across LLM results and in comparison, to the expert-authored trial report highlight the need for highly trained subject matter experts to review and revise LLM-generated clinical trial analyses.


  • Open Access

    From organs to algorithms: Redefining cancer classification in the age of artificial intelligence

    by Sean Khozin

    Traditional cancer classification based on organ of origin and histology is increasingly at odds with precision oncology. Tumors in different organs can share molecular features, while those in the same organ can be heterogeneous. This disconnect impacts clinical trials, drug development, and patient care. Recent advances in artificial intelligence (AI), particularly machine learning and deep learning, offer promising avenues for reclassifying cancers through comprehensive integration of molecular, histopathological, imaging, and clinical characteristics. AI‐driven approaches have the potential to reveal novel cancer subtypes, identify new prognostic variables, and guide more precise treatment strategies for improving patient outcomes.


  • Open Access

    Non-Obvious Alien AI Constructions: Opportunities and Implications

    by Sean Khozin

    This paper examines the utility and exploitation of non-obvious "alien" AI constructions, artificial intelligence solutions that significantly deviate from human intuition and traditional problem-solving approaches. It explores recent revelations, key characteristics, applications across various domains, and far-reaching implications for scientific research and innovation. Particular attention is given to developments in mathematical reasoning, drug discovery, and healthcare. The paper also discusses challenges in implementation, ethical considerations, and future directions, including meta-learning algorithms and human-AI collaboration frameworks. By synthesizing current research and identifying emerging trends, this paper aims to provide a basic understanding of the transformative potential of non-obvious AI solutions in reshaping scientific discovery and biomedical innovation.


  • Real-World Evidence In Support Of Precision Medicine: Clinico-Genomic Cancer Data As A Case Study

    by Vineeta Agarwala, Sean Khozin, Gaurav Singal, Claire O’cOnnell, Deborah Kuk, Gerald Li, Anala Gossai, Vincent Miller, Amy P. Abernethy

    The majority of US adult cancer patients today are diagnosed and treated outside the context of any clinical trial (that is, in the real world). Although these patients are not part of a research study, their clinical data are still recorded. Indeed, data captured in electronic health records form an ever-growing, rich digital repository of longitudinal patient experiences, treatments, and outcomes. Likewise, genomic data from tumor molecular profiling are increasingly guiding oncology care. Linking real-world clinical and genomic data, as well as information from other co-occurring data sets, could create study populations that provide generalizable evidence for precision medicine interventions. However, the infrastructure required to link, ensure quality, and rapidly learn from such composite data is complex. We outline the challenges and describe a novel approach to building a real-world clinico-genomic database of patients with cancer. This work represents a case study in how data collected during rou...


  • Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval

    by Sean Khozin, Amy P. Abernethy, Nathan C. Nussbaum, Jizu Zhi, Melissa D. Curtis, Melisa Tucker, Shannon E. Lee, David E. Light, Anala Gossai, Rachael A. Sorg, et al.

    Background. Evidence from cancer clinical trials can be difficult to generalize to real‐world patient populations, but can be complemented by real‐world evidence to optimize personalization of care. Further, real‐world usage patterns of programmed cell death protein 1 (PD‐1) inhibitors following approval can inform future studies of subpopulations underrepresented in clinical trials. Materials and Methods. We performed a multicenter analysis using electronic health record data collected during routine care of patients treated in community cancer care clinics in the Flatiron Health network. Real‐world metastatic non‐small cell lung cancer (NSCLC) patients who received nivolumab or pembrolizumab in the metastatic setting (n = 1,344) were selected from a starting random sample of 55,969 NSCLC patients with two or more documented visits from January 1, 2011, through March 31, 2016. The primary study outcome measurement was demographic and treatment characteristics of the cohort. Results. Median age at PD‐1 inhibitor initiation was 69 years (interquartile range 61–75). Patients were 56% male, 88% smokers, 65% nonsquamous histology, and 64% diagnosed at stage IV. Of 1,344 patients, 112 (8%) were tested for programmed death‐ligand 1 expression. Overall, 50% received nivolumab or pembrolizumab in the second line, with a substantial proportion of third and later line use that began to decline in Q4 2015. Conclusion. During the year following U.S. regulatory approval of PD‐1 inhibitors for treatment of NSCLC, real‐world patients receiving nivolumab or pembrolizumab were older at treatment initiation and more had smoking history relative to clinical trial cohorts. Studies of outcomes in underrepresented subgroups are needed to inform real‐world treatment decisions. Implications for Practice. Evidence gathered in conventional clinical trials used to assess safety and efficacy of new therapies is not necessarily generalizable to real‐world patients receiving these drugs following regulatory approval. Real‐world evidence derived from electronic health record data can yield complementary evidence to enable optimal clinical decisions. Examined here is a cohort of programmed cell death protein 1 inhibitor‐treated metastatic non‐small cell lung cancer patients in the first year following regulatory approval of these therapies in this indication. The analysis revealed how the real‐world cohort differed from the clinical trial cohorts, which will inform which patients are underrepresented and warrant additional studies.


  • Core Clinical Data Elements for Cancer Genomic Repositories: A Multi-stakeholder Consensus

    by Robert B. Conley, Dane Dickson, Jean Claude Zenklusen, Jennifer Al Naber, Donna A. Messner, Ajlan Atasoy, Lena Chaihorsky, Deborah Collyar, Carolyn Compton, Martin Ferguson, et al.